Tool
Stock screener
Filter the 3753 large-cap US stocks StockVane tracks, then sort by any column. Results carry the same Quant Rating shown on each stock’s page.
Top Quant-ratedLarge-cap dividend payersCheap & top-ratedBeaten-down (down 20%+ 1yr)High yield (4%+)Mega-cap winners
177 matches
| Company | 60d | Last | Chg% | Mkt cap | P/E | Yield | 1-yr | Quant ↑ |
|---|---|---|---|---|---|---|---|---|
| BlossomHill TherapeuticsBLSM | 16.61 | -3.93% | $527.95M | -- | -- | -- | -- | |
| ELECTRA THERAPEUTICS INCETRA | 9.16 | -6.72% | $559.68M | -- | -- | -- | -- | |
| Puma BiotechnologyPBYI | 9.81 | +3.26% | $506.39M | 19.24 | -- | +87.6% | -- | |
| Theravance Biopharma(Delisted)TBPH | 17.03 | 0.00% | $884.18M | 16.38 | -- | -- | -- | |
| VeradermicsMANE | 110.95 | +1.83% | $4.64B | -- | -- | -- | C 0 | |
| Parabilis MedicinesPBLS | 28.82 | -0.14% | $3.56B | -- | -- | -- | C 0 | |
| AtaiBeckleyATAI | 7.35 | 0.00% | $2.73B | -- | -- | -- | C 0 | |
| Braveheart BioBRVE | 18.58 | -6.11% | $1.67B | -- | -- | -- | C 0 | |
| Generate BiomedicinesGENB | 13.57 | -1.67% | $1.74B | -- | -- | -- | C 0 | |
| Hemab Therapeutics HoldingsCOAG | 28.70 | +1.16% | $1.34B | -- | -- | -- | C 0 | |
| KardiganKARD | 13.83 | +2.52% | $1.29B | -- | -- | -- | C 0 | |
| Kailera TherapeuticsKLRA | 10.53 | -2.77% | $1.37B | -- | -- | -- | C 0 | |
| Ascentage PharmaAAPG | 14.94 | -7.15% | $1.40B | -- | -- | -62.9% | E 1 | |
| uniQure NVQURE | 23.14 | +0.35% | $1.61B | -- | -- | -61.4% | E 2 | |
| Alnylam PharmaceuticalsALNY | 224.41 | +0.21% | $30.03B | 39.10 | -- | -50.2% | E 3 | |
| Ultragenyx PharmaceuticalRARE | 14.89 | +2.97% | $1.47B | -- | -- | -51.7% | E 3 | |
| Intellia TherapeuticsNTLA | 11.71 | -5.34% | $1.64B | -- | -- | -52.1% | E 5 | |
| Legend BiotechLEGN | 19.12 | +2.14% | $3.72B | -- | -- | -40.6% | E 7 | |
| MannKindMNKD | 3.45 | -7.01% | $1.11B | -- | -- | -36.6% | E 7 | |
| InsmedINSM | 101.74 | -3.32% | $22.22B | -- | -- | -37.1% | E 8 | |
| Ionis PharmaceuticalsIONS | 44.16 | +0.36% | $7.34B | -- | -- | -36.9% | E 8 | |
| Ocular TherapeutixOCUL | 7.23 | -1.50% | $1.59B | -- | -- | -39.3% | E 9 | |
| NewAmsterdam PharmaNAMS | 22.13 | -0.63% | $2.65B | -- | -- | -32.7% | E 10 | |
| CRISPR TherapeuticsCRSP | 52.35 | -3.06% | $5.06B | -- | -- | -31.8% | E 14 | |
| BiohavenBHVN | 11.88 | -1.66% | $1.79B | -- | -- | -22.6% | E 14 | |
| Sarepta TherapeuticsSRPT | 17.50 | +1.10% | $1.85B | -- | -- | -25.1% | E 14 | |
| Zai LabZLAB | 25.31 | -1.06% | $2.84B | -- | -- | -24.9% | D 15 | |
| Recursion PharmaceuticalsRXRX | 4.27 | -7.78% | $2.29B | -- | -- | -29.9% | D 16 | |
| Summit TherapeuticsSMMT | 17.95 | +3.70% | $14.32B | -- | -- | -23.1% | D 19 | |
| MesoblastMESO | 13.94 | +2.42% | $1.81B | -- | -- | -29.4% | D 19 | |
| Caris Life SciencesCAI | 27.10 | -1.29% | $7.66B | 72.85 | -- | -17.8% | D 20 | |
| Lakefront BiotherapeuticsLKFT | 30.00 | +2.32% | $1.96B | 2.96 | -- | -13.0% | D 22 | |
| Viridian TherapeuticsVRDN | 18.28 | +0.33% | $2.07B | -- | -- | -14.4% | D 25 | |
| Viking TherapeuticsVKTX | 28.54 | +0.56% | $3.59B | -- | -- | -11.8% | D 26 | |
| Disc MedicineIRON | 61.18 | -0.76% | $2.35B | -- | -- | -12.9% | D 26 | |
| Rhythm PharmaceuticalsRYTM | 88.45 | -2.56% | $6.09B | -- | -- | -11.8% | D 27 | |
| BioNTechBNTX | 95.25 | -0.50% | $23.93B | -- | -- | -10.4% | D 28 | |
| Xenon PharmaceuticalsXENE | 36.41 | -0.44% | $3.53B | -- | -- | -7.2% | D 29 | |
| Structure TherapeuticsGPCR | 26.68 | -2.88% | $1.90B | -- | -- | -6.2% | D 31 | |
| Bicara TherapeuticsBCAX | 16.42 | -0.85% | $1.09B | -- | -- | -8.8% | F 33 | |
| OculisOCS | 8.50 | -2.52% | $523.50M | -- | -- | -57.2% | F 33 | |
| Phathom PharmaceuticalsPHAT | 6.81 | +0.44% | $550.94M | -- | -- | -38.4% | F 34 | |
| RegenxbioRGNX | 7.60 | +1.95% | $501.37M | -- | -- | -37.8% | F 34 | |
| Maze TherapeuticsMAZE | 26.25 | -0.68% | $1.46B | -- | -- | -8.2% | D 34 | |
| InventivaIVA | 3.37 | -2.75% | $794.93M | -- | -- | -37.2% | F 35 | |
| SL ScienceSLBT | 1.51 | -0.66% | $846.75M | -- | -- | -85.4% | F 35 | |
| Latigo BiotherapeuticsLTGO | 15.52 | -4.55% | $1.03B | -- | -- | -- | F 36 | |
| PTC TherapeuticsPTCT | 63.23 | -0.74% | $5.28B | -- | -- | -1.9% | D 36 | |
| Vera TherapeuticsVERA | 30.25 | +2.82% | $2.18B | -- | -- | -0.8% | D 36 | |
| Sana BiotechnologySANA | 2.72 | -1.09% | $814.26M | -- | -- | -40.0% | F 38 | |
| Biomarin PharmaceuticalBMRN | 55.20 | -1.81% | $10.69B | 145.26 | -- | +0.9% | D 38 | |
| Abivax S.A.ABVX | 87.01 | -1.37% | $7.59B | -- | -- | +0.6% | D 39 | |
| Taysha Gene TherapiesTSHA | 4.43 | +0.91% | $1.44B | -- | -- | -12.5% | D 39 | |
| DBV TechnologiesDBVT | 9.77 | -2.10% | $614.03M | -- | -- | -38.5% | D 40 | |
| Avalyn PharmaAVLN | 25.53 | +0.39% | $1.13B | -- | -- | -- | D 41 | |
| Kura OncologyKURA | 10.67 | +1.33% | $949.21M | -- | -- | +5.9% | D 41 | |
| Wave Life SciencesWVE | 3.54 | +0.57% | $697.55M | -- | -- | -51.8% | D 41 | |
| Aktis OncologyAKTS | 18.00 | +0.78% | $1.00B | -- | -- | -- | D 42 | |
| CytomXCTMX | 2.55 | -0.39% | $555.64M | -- | -- | -24.3% | D 42 | |
| ImmaticsIMTX | 7.45 | -0.67% | $1.11B | -- | -- | -28.2% | D 42 |
Reference only, not investment advice. A screen is a starting point, not a buy list. Quant Rating method: Data & Methodology.